Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of September 2021. The report serves as a Director Declaration pursuant to the Financial Conduct Authority's Listing Rule 9.6.14(2).
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a corporate governance announcement and does not contain financial performance data.
Material Changes
The filing announces a material change in the external directorships of GSK's board. Dr. Vivienne Cox CBE, a Non-Executive Director of GSK, has been appointed to the board of Victrex plc. Her roles are scheduled as follows:
- Non-Executive Director of Victrex plc: Effective 1 December 2021.
- Chair-designate of Victrex plc: Effective 1 January 2022.
- Chair of Victrex plc: Effective 11 February 2022.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, outlook, management commentary on operations, risks, contingencies, or unusual items. The document is limited to the disclosure of the director appointment.
Key Facts for Investor Verification
- Dr. Vivienne Cox CBE is assuming new external leadership roles at Victrex plc while remaining a Non-Executive Director at GSK.
- The appointment timeline spans from December 2021 to February 2022.
- No financial results or operational updates are included in this specific filing.